News Home

Is Cidara Therapeutics Inc (CDTX) a Poor Choice in the Healthcare Sector?

Friday, January 27, 2023 03:41 PM | InvestorsObserver Analysts

Mentioned in this article

Is Cidara Therapeutics Inc (CDTX) a Poor Choice in the Healthcare Sector?

Cidara Therapeutics Inc (CDTX) is near the bottom in its sector according to InvestorsObserver. CDTX gets an overall rating of 0. That means it scores higher than 0% of stocks. Cidara Therapeutics Inc gets a 0 rank in the Healthcare sector. Healthcare is number 4 out of 11 sectors.

Overall Score - 0
CDTX has an Overall Score of 0. Find out what this means to you and get the rest of the rankings on CDTX!

What do These Ratings Mean?

Trying to find the best stocks can be a daunting task. There are a wide variety of ways to analyze stocks in order to determine which ones are performing the strongest. *Investors Observer* makes the entire process easier by using percentile rankings that allows you to easily find the stocks who have the strongest evaluations by analysts. Not only are these scores easy to understand, but it is easy to compare stocks to each other. You can find the best stock in healthcare or look for the sector that has the highest average score. The overall score is a combination of technical and fundamental factors that serves as a good starting point when analyzing a stock. Traders and investors with different goals may have different goals and will want to consider other factors than just the headline number before making any investment decisions.

What's Happening With Cidara Therapeutics Inc Stock Today?

Cidara Therapeutics Inc (CDTX) stock is flat -0.41% while the S&P 500 is higher by 0.68% as of 3:41 PM on Friday, Jan 27. CDTX is unmoved $0.00 from the previous closing price of $1.21 on volume of 1,428,880 shares. Over the past year the S&P 500 is lower by -5.51% while CDTX is higher by 57.14%. CDTX lost -$0.53 per share the over the last 12 months. Click Here to get the full Stock Report for Cidara Therapeutics Inc stock.

You May Also Like

Get the InvestorsObserver App

InvestorsObserver App
iOS App Android App